Author

Eva Doelger

Institution: AbbVie (Germany)

Observed institution: AbbVie (Germany)

OpenAlex ID: A5004380183

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

2019 · Ahmed Nader, Mohamed‐Eslam F. Mohamed, et al. · Clinical Pharmacology & Therapeutics · 28

Population pharmacokinetic and exposure‐response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis

2023 · Mohamed Ismail, Eva Doelger, et al. · British Journal of Clinical Pharmacology · 14

Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety

2023 · Mohamed Badawi, Sheryl Coppola, et al. · Hematological Oncology · 7

Fri0138 Exposure-response Analyses of Upadacitinib Efficacy and Safety in Rheumatoid Arthritis – Analyses of Phase 2 and 3 Studies

2019 · Mohamed-Eslam Mohamed, Ahmed Nader, et al. · Annals of the Rheumatic Diseases · 2

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

2022 · Mohamed A Badawi, Sheryl Coppola, et al. · Blood

Works count: 5

Citation count: 51

H-index: 3

I10-index: 2